Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in CPPD (BAPTIST)
NCT06768294Phase 2Not yet recruiting
- Sponsor
- IRCCS Ospedale Galeazzi-Sant'Ambrogio
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in calcium pyrophosphate deposition disease (CPPD), sponsored by IRCCS Ospedale Galeazzi-Sant'Ambrogio. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
calcium pyrophosphate deposition disease (CPPD)
Beyond the preview
Go deeper on NCT06768294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06768294.